Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.56 |
| ▸ | TNKS | O95271 | 1/20 | 0.56 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | C1S | P09871 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9448432 | 0.92 | PRSS1 (0.58) | PARP1PRSS1PARP10TNKSPARP15 | |
| SCHEMBL14791423 | 0.89 | PRSS1 (0.62) | PARP1PRSS1PARP10TNKSPARP15 | |
| SCHEMBL13445952 | 0.88 | PARP1 (0.57) | PARP1PRSS1PARP10TNKSPARP15 | |
| SCHEMBL1572959 | 0.86 | KMT2A (0.71) | PRSS1KMT2ATAAR1 | |
| SCHEMBL30938280 | 0.86 | PARP1 (0.59) | PARP1PRSS1PARP10TNKSPARP15 | |
| SCHEMBL4326927 | 0.86 | PARP1 (0.59) | PARP1PRSS1PARP10TNKSPARP15 | |
| SCHEMBL28029093 | 0.86 | PARP1 (0.62) | PARP1PRSS1PARP10TNKSPARP15 | |
| Hydrochloric Acid SCHEMBL25378558 | 0.85 | KMT2A (0.69) | PRSS1KMT2ATAAR1 | |
| SCHEMBL3072792 | 0.85 | PRSS1 (0.58) | PARP1PRSS1PARP10TNKSPARP15 | |
| SCHEMBL201524 | 0.85 | KMT2A (0.73) | PARP1PRSS1PARP10TNKSPARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563073-B | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| EP-3475268-B1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3475268-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2019-05-01 | — | — | EP | disclosed |
| CN-109563073-A | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2017220799-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2017-12-28 | — | — | WO | disclosed |
| EP-3260452-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2017-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | HTR5A, HTR1A, HTR1E | PARP1 427/4885PRSS1 2165/4885PARP10 122/4885 |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR1E | PARP1 427/4885PRSS1 2165/4885PARP10 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.